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Abstract
Background: Definite identification of the cell types and the mechanism relevant to cardiomyogenesis is essential for
effective cardiac regenerative medicine. We aimed to identify the cell populations that can generate cardiomyocytes and to
clarify whether generation of donor-marker+ cardiomyocytes requires cell fusion between BM-derived cells and recipient
cardiomyocytes.
Methodology/Principal Findings: Purified BM stem/progenitor cells from green fluorescence protein (GFP) mice were
transplanted into C57BL/6 mice or cyan fluorescence protein (CFP)-transgenic mice. Purified human hematopoietic stem
cells (HSCs) from cord blood were transplanted into immune-compromised NOD/SCID/IL2rcnull mice. GFP+ cells in the
cardiac tissue were analyzed for the antigenecity of a cardiomyocyte by confocal microscopy following immunofluores-
cence staining. GFP+ donor-derived cells, GFP+CFP+ fused cells, and CFP+ recipient-derived cells were distinguished by linear
unmixing analysis. Hearts of xenogeneic recipients were evaluated for the expression of human cardiomyocyte genes by
real-time quantitative polymerase chain reaction. In C57BL/6 recipients, Lin2/lowCD45+ hematopoietic cells generated
greater number of GFP+ cardiomyocytes than Lin2/lowCD452 mesenchymal cells (37.0+/223.9 vs 0.00+/20.00 GFP+
cardiomyocytes per a recipient, P = 0.0095). The number of transplanted purified HSCs (Lin2/lowSca-1+ or Lin2Sca-1+c-Kit+ or
CD342Lin2Sca-1+c-Kit+) showed correlation to the number of GFP+ cardiomyocytes (P,0.05 in each cell fraction), and the
incidence of GFP+ cardiomyocytes per injected cell dose was greatest in CD342Lin2Sca-1+c-Kit+ recipients. Of the
hematopoietic progenitors, total myeloid progenitors generated greater number of GFP+ cardiomyocytes than common
lymphoid progenitors (12.8+/210.7 vs 0.67+/21.00 GFP+ cardiomyocytes per a recipient, P = 0.0021). In CFP recipients, all
GFP+ cardiomyocytes examined coexpressed CFP. Human troponin C and myosin heavy chain 6 transcripts were detected in
the cardiac tissue of some of the xenogeneic recipients.
Conclusions/Significance: Our results indicate that HSCs resulted in the generation of cardiomyocytes via myeloid
intermediates by fusion-dependent mechanism. The use of myeloid derivatives as donor cells could potentially allow more
effective cell-based therapy for cardiac repair.
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Introduction
Modification of regenerative capacity in injured heart could be
potentially alternative to conventional therapy for treating patients
suffering from heart failure [1–7]. Based on the promising results
in rodents [3,4], clinical trials of cellular therapy using bone
marrow (BM) cells for ischemic heart disease patients have been
designed. In many of clinical trials for improving the function of
cardiac recovery, some favorable results were obtained following
injection of BM mononuclear cells (MNCs) [2,5–7]. However,
careful examination needs to be performed in basic research
because cell fate and the effects of transplanted cells are not fully
unveiled [8].
BM contains heterogeneous cell populations including at least
two distinct stem cells, hematopoietic stem cells (HSCs) and
mesenchymal stem cells (MSCs) [9], and various progenitors of
myeloid and lymphoid lineages. Both HSCs and MSCs have been
reported to acquire the phenotype of cardiomyocytes in syngeneic
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or xenogeneic recipients [4,10–13]. However, quantitative analysis
of regenerative capacity by each stem fraction has not been
performed in the identical transplantation setting.
One proposed mechanism for the phenotypic change of BM-
derived cells to tissue-specific cells is cell fusion. Since the original
report of spontaneous cell fusion between BM cells and embryonic
stem cells [14], it has become apparent that not only some BM-
derived cells in the heart and other selective tissues are the
consequences of cell fusion at least in part [10,12,15], but also
fused BM-derived cells can be reprogrammed to express tissue
specific genes [16,17]. On the other hand, BM cells have been
reported to generate non-hematopoietic cells in certain tissues
without fusion requirement [18,19] although cell fate conversion
from HSCs themselves directly to cardiomyocytes has questioned
in several studies [10,20,21].
To improve the efficiency of cardiac functional restoration and
to minimize adverse effects of cell-based therapy using BM cells,
the cell type with the greatest contribution to cardiomyogenesis
and mechanisms underlying altered cardiac function need to be
clarified in vivo. In this study, we examined cardiomyogenic
potential of BM cells following syngeneic BM transplantation to
identify the cell population in BM that possesses cardiomyogenic
potential and to clarify whether cardiomyogenesis by BM-derived
cells require cell fusion with recipient cardiomyocytes. Further-
more, we adopted xenogeneic transplantation system to unveil
genetic sequences of donor-derived cardiomyocytes through
discrimination of the donor gene from the recipient gene. To
fully exploit the capacity of stem cells, we employed newborns as
recipients, in which age-related decline of regenerative capacity
can be restored by environmental factors [22].
Results
Determination of Cell Fate in Cardiac Tissue of Recipient
Mice Transplanted with Syngeneic BM Cells
We first created an in vivo model for evaluating cell fate of BM
cells in cardiac tissue by injecting 107 unfractionated green
fluorescence protein (GFP) mouse BM cells into irradiated
newborn C57BL/6 mice, followed by ventricular puncture. In
the recipients, we detected GFP+ cells preferentially located
adjacent to the injured cites. GFP+ cells in recipient cardiac tissues
included CD45+ or CD11b+ hematopoietic cells (Figure 1A),
vimentin+ fibroblasts (Figure 1B), cardiac troponin I (TnI)+ and/or
Connexin 43 (Cx43)+ cardiomyocytes (Figure 1C and 1D)
indicating that the system could be used for analyzing differ-
entiative and regenerative properties of donor stem/progenitor
cells. Cardiomyocytes were counted by their specific intracellular
striated structure and longer diameter compared with hematopoi-
etic cells. Immunofluorescence studies confirmed that the counted
cells were cardiomyocytes as evidenced by the expression of TnI.
Since the frequencies of GFP+ cardiomyocytes were similar in
recipients transplanted with total BM cells or in those transplanted
with Lin2/low MNCs, we postulated that the cardiomyogenic cells
in BM are enriched in immature Lin2/lowMNCs.
BM-derived Cardiomyocytes Originate from the
Hematopoietic Lineage
We next determined the contribution of HSCs and MSCs, two
already-defined stem cells in BM, to the generation of GFP+
cardiomyocytes. Multi-lineage differentiation capacities of HSCs
included in the CD45+ fraction and MSCs included in the CD452
fraction were confirmed by the development of lymphoid and
myeloid cells in vivo and the induction of osteoblasts and adipocytes
in vivo and in vitro, respectively (see Figure S1). To compare the
cardiomyogenic abilities, 1.86106–4.46107 Lin2/lowCD45+ cells
and 3.66105–2.56106 Lin2/lowCD452 cells from GFP mice were
transplanted into syngeneic recipients. At 4–6 weeks after
transplantation, GFP+ cardiomyocytes were detected only in
recipients transplanted with Lin2/lowCD45+ cells (n = 6). By
contrast, GFP+ cardiomyocytes were not detected in recipients
transplanted with Lin2/lowCD452 cells (n = 4; P= 0.0095 Lin2/
lowCD45+ versus Lin2/lowCD452; Table 1) nor in the recipient
transplanted with purified GFP+Lin2CD452 cells. These findings
suggest that donor-derived cardiomyocytes following BM trans-
plantation originate from the hematopoietic lineage at least in this
transplantation setting.
Transplantation of Purified BM HSC Fraction Resulted in
the Efficient Production of Donor-derived
Cardiomyocytes
Next, we aimed to assess the cardiomyogenic ability of purified
hematopoietic stem/progenitor population. We transplanted
limiting numbers of GFP+Lin2/lowSca1+ cells including HSCs
and hematopoietic progenitors, purified GFP+Lin2Sca-1+c-Kit+
cells (LSKs; Figure 2A) including HSCs and multipotent
progenitors, and purified GFP+CD342Lin2Sca-1+c-Kit+ cells
(CD342LSKs; Figure 2A) which contain HSCs that have long-
term self-renewing potential. In all recipients transplanted with
above three types of cells, GFP+ cells of myeloid lineage, B cell
lineage, and T cell lineage were present in peripheral blood (PB)
and BM (see Figure S2). The numbers of GFP+ cardiomyocytes
significantly correlated with the injected cell dose in each group of
the recipients transplanted with 103–106 Lin2/lowSca-1+ cells from
GFP mice, 103–1.86105 GFP+LSKs, and 1–103
GFP+CD342LSKs (P,0.05 in all groups; Figure 2C–E, Table 1).
Furthermore, the incidence of GFP+ cardiomyocytes per injected
cell dose was greatest in GFP+CD342LSKs recipients followed by
that in GFP+LSKs recipients, and the incidence in GFP+Lin2/
lowSca-1+ recipients was the lowest (Figure 2F, Table 1). GFP+
cardiomyocytes were detected following transplantation of as few
as 10 GFP+CD342LSKs. We further confirmed contribution of
self-renewing HSCs to the generation of cardiomyocytes by
secondary and tertiary BM transplantation from GFP+LSK
recipients (see Table S1). These findings indicate that BM cells
with cardiomyogenic capacity are highly enriched within the
CD342LSK HSC population.
Myeloid Lineage Cells are the Primary Intermediates for
Generating Cardiomyocytes
Since the capacity of HSCs to convert directly into cardiomy-
ocytes has yet to be determined [18–21], we examined the
capacity of hematopoietic progenitors to act as relevant interme-
diates for cardiomyogenesis. At 4 weeks after transplantation of
1.26104–1.46106 fluorescence-activated cell sorting (FACS)-puri-
fied GFP+Lin2Thy1.22Sca-12/lowc-Kit+/low cells which mainly
contain mixed myeloid and lymphoid progenitor population,
GFP+ cardiomyocytes were identified in all recipients (n = 10;
Table 1). This result indicates that transplanted HSCs give rise to
cardiomyocytes via hematopoietic intermediates, at least partly.
To discriminate the hematopoietic lineage required in cardio-
myogenesis, we then transplanted 0.4–2.86105 FACS-purified
GFP+Lin2Thy1.22interleukin-7 receptor a-chain (IL-7Ra)2Sca-
12c-Kit+ total myeloid progenitors (n = 7) and 0.2–3.36105
GFP+Lin2Thy1.22IL-7Ra+Sca-1lowc-Kitlow common lymphoid
progenitors (CLPs; n= 9) sorted simultaneously from the same
GFP+ BM cells (Figure 2B). At 3–6 weeks after transplantation,
recipients of myeloid progenitors showed predominant GFP+
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myeloid engraftment while recipients of CLPs showed predomi-
nant GFP+ lymphoid engraftment in PB (see Figure S2). Although
recipients of myeloid progenitors and CLPs showed similar PB
GFP+ engraftment (Table 1), significantly greater number of GFP+
cardiomyocytes were identified in recipients transplanted with
myeloid progenitors than in those transplanted with CLPs
(P= 0.0021; Table 1). We further confirmed the contribution of
myeloid cells to the generation of cardiomyocytes by transplan-
tation of GFP+Lin2IL-7Ra2Sca-12c-Kit+ Fcc receptor-II/III
(FccR)lowCD34+ common myeloid progenitor (CMPs; 0.3–
1.06105, n= 6; Table 1) and GFP+Lin2IL-7Ra2Sca-12c-
Kit+FccRhighCD34+ granulocyte/monocyte progenitors (GMPs;
Figure 1. Characterization of donor BM-derived GFP+ cells in injured heart. (A) Representative image of CD11b-expressing GFP+ myeloid
cells. GFP+ hematopoietic cells in recipient cardiac tissue appeared in small and round shape. Cardiac section was stained with anti-CD11b (red, Cy3)
and DAPI (blue). Inset: high magnification of GFP+CD11b+ cells. (B) Representative image of a vimentin-expressing GFP+ fibroblast. Cardiac section
was stained with anti-vimentin (red, Cy3). The fibroblast was present adjacent to striated cardiomyocytes in differential interference contrast (DIC)
image. (C and D) Representative images of a TnI- (C) or Cx43- (D) expressing GFP+ striated cardiomyocyte. Cardiac sections were stained with anti-TnI
(C; red, Cy3), anti-Cx43 (D; yellow, Cy5), and DAPI (blue). Cardiac sections are from recipients transplanted with unfractionated BM cells. All merged
images were obtained from the same confocal plane. Scale bars = 50 mm, (A)-inset 10 mm.
doi:10.1371/journal.pone.0062506.g001
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0.9–1.36105, n = 4; Table 1). These findings suggest that myeloid
derivatives are responsible for providing cardiomyocytes in
recipients.
Cell Fusion is the Major Mechanism Underlying the
Generation of BM-derived Cardiomyocytes
To explore the mechanism of BM-derived cardiomyocyte
generation, BM cells of GFP mice were transplanted into cyan
fluorescence protein (CFP)-transgenic newborn mice. At 4–22
weeks after transplantation of unfractionated BM cells, LSK,
Lin2Thy1.22Sca-12/lowc-Kit+/low, Lin2/lowSca-1+, and Lin2/low-
Sca-1
2
cells from GFP mouse BM, 1–166 GFP+ cardiomyocytes
per a mouse were detected in CFP recipients (n = 11). The
incidence of GFP+ cardiomyocytes in CFP recipients was
comparable to that in C57BL/6 recipients, suggesting that the
cardiomyogenic event is not influenced by employing CFP-
transgenic mice as recipients. The emitted fluorescence from
recipient cardiac sections stained with cardiac TnI-cyanin-3 (Cy3),
Cx43-cyanin-5 (Cy5), and 49,6-diaimidino-2-phenylindole (DAPI)
was detected at 10–11 nm interval from 417 nm to 749 nm
wavelength using a laser-scanning confocal microscope (Figure 3A).
The presence of cyan fluorescence in multiple points of each
GFP+TnI+Cx43+ cardiomyocyte was examined by using linear
unmixing analysis (see Materials and Methods S1). Irrespective of
the donor cell type, all 21 GFP+ cardiomyocytes detected in the
cardiac tissues of 8 recipients coexpressed CFP (Figure 3B and 3C,
see Table S2), suggesting that BM-derived cardiomyocytes are
generated through cell fusion between BM-derived cells and
recipient-derived cardiomyocytes.
Analysis of Cardiomyocyte-specific Genes in Mice
Transplanted with Human Cord Blood HSCs
Finally, we aimed to clarify whether donor hematopoietic cells
can change their cell fate through cell fusion with host
cardiomyocytes. To this end, we set up xenogeneic transplantation
by injecting human cord blood-derived CD34+CD382 HSCs into
immune-compromised mice (NOD/SCID/IL2rcnull mice [23],
NOD.Rag1nullIL2rcnull mice [24], and C57BL/6.Rag2nullIL2rc-
nullNOD-Sirpa mice [25]). We extracted ribonucleic acid (RNA)
from recipient cardiac tissues and performed quantitative real-time
polymerase chain reaction (qRT-PCR) to detect human-specific
cardiac transcription factors (Gata-4 [GATA4], Tbx 5 [TBX5],
Nkx 2.5 [NKX2–5], and Mesp 1 [MESP1]) [26] and cardiomy-
ocyte structural genes (a-myosin heavy chain 6 [MYH6] and
cardiac troponin C [TNNC1], connexin 43 [GJA1], and
ryanodine receptor 2 [RYR2]). Of cardiac transcription factors,
Gata-4, Tbx 5, and Mesp 1 were not expressed in any of the
examined 14 recipients. Although Nkx 2.5 was expressed in 2 of
Table 1. The number of donor-derived cardiomyocytes after transplantation of purified BM cells.
Donor cell type Cell dose n
Days after
injection BM %GFP+ PB %GFP+
GFP+
cardiomyocytes*
Hematopoietic cell Lin2/lowCD45+ 0.2–4.46107 6 25–46 86.7+/213.9 90.6+/25.6 37.0+/223.9a
Mesenchymal cell Lin2/lowCD452 0.4–2.56106 4 25–39 0.35+/20.39 0.03+/20.05 0.00+/20.00a
HSC Lin2/lowSca-1+ 106 5 29–34 83.2+/26.6 96.4+/22.9 33.9+/216.0
105 5 29–39 54.8+/217.8 75.5+/217.0 21.8+/210.7
104 5 28–39 3.0+/21.6 6.0+/27.6 4.2+/23.4
103 5 28–39 0.59+/20.40 1.6+/22.5 1.2+/21.1
LSK 1.0–1.86105 6 27–44 76.6+/217.7 89.1+/217.0 33.6+/243.1
1.0–4.06104 8 31–52 36.2+/225.1 45.0+/232.8 9.3+/210.3
1.0–2.06103 6 31–52 25.5+/223.3 38.2+/227.6 2.4+/22.0
CD342LSK 103 2 28–50 66.8+/227.3 67.3+/223.6 12.5+/25.0
102 3 31–57 6.7+/210.9 15.5+/214.9 3.4+/22.5
10 7 213–354 0.19+/20.13 0.05+/20.05 0.14+/20.38
1 34 116–378 0.12+/20.21 0.06+/20.09 0.00+/20.00
Hematopoietic
progenitor
Lin2Thy1.22Sca-12/lowc-kit+/
low
1.2–1.46106 3 29–31 62.9+/218.7 82.3+/24.4 16.9+/28.2
1.2–4.76105 3 27–29 37.9+/221.3 51.8+/227.5 14.4+/27.4
1.2–3.06104 4 21–29 4.6+/25.3 3.8+/22.4 10.8+/24.4
Myeloid progenitor 0.4–2.86105 7 24–39 4.2+/25.2 3.6+/24.1 d 12.8+/210.7b
CMP 0.3–1.06105 6 31–42 0.87+/20.70 0.52+/20.59 17.2+/27.3 c
GMP 0.9–1.36105 4 24–42 1.5+/22.4 11.0+/222.0 6.6+/25.9
CLP 0.2–3.36105 9 24–39 4.0+/24.7 8.7+/26.8d 0.67+/21.00b,c
aP = 0.0095 by Mann-Whitney U test, Lin2/lowCD45+ versus Lin2/lowCD452.
bP = 0.0021 by Mann-Whitney U test, Myeloid progenitor versus CLP.
cP = 0.0004 by Mann-Whitney U test, CMP versus CLP.
dP = 0.1142 by Mann-Whitney U test, Myeloid progenitor versus CLP.
*GFP+ cardiomyocytes were counted in 40 contiguous sections from apex of the heart per a mouse. Detailed information of histological analysis is described in Materials
and Methods, Materials and Methods S1.
Abbreviations. BM: bone marrow, PB: peripheral blood, HSC: hematopoietic stem cell, LSK: Lin2Sca-1+c-Kit+, CMP: common myeloid progenitor, GMP: granulocyte/
monocyte progenitor, CLP: common lymphoid progenitor.
doi:10.1371/journal.pone.0062506.t001
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14 recipients, the expression of Nkx 2.5 was not specific to human
cardiomyocytes since it was expressed in human cord blood [27]
(see Table S3). Of cardiomyocyte structural genes, human myosin
heavy chain 6 and troponin C were expressed in 1 of 14 and 9 of
14 recipients, respectively. Specificity of these probes to human
cardiomyocytes was confirmed by the positive reaction to human
Figure 2. Transplantation of HSCs and hematopoietic progenitors. (A) LSKs or CD342LSKs were purified by FACS from Lin2/lowc-Kit+ BM
fraction of GFP mice. GFP and Lineage+propidium iodide (PI) expression of unfractionated BM cells is shown as a control. (B) Total myeloid
progenitors (My-P) and CLPs were purified by FACS from Lin2/lowThy1.22/lowMNCs of GFP mice. (C-E) Correlational analyses between injected cell
numbers and the numbers of GFP+ cardiomyocytes per a recipient mouse in recipients transplanted with Lin2/lowSca-1+ cells (C), LSKs (D), and
CD342LSKs (E). (F) Comparison of the number of GFP+ cardiomyocytes at the same injected cell dose in Lin2/lowSca-1+ cells, LSKs, and CD342LSKs
recipients. The means of the number of GFP+ cardiomyocytes in recipients transplanted with each injected cell number are plotted. In the
transplantation of LSKs, injected cell number of 1–1.86105 cells is plotted at 105, that of 1–46104 cells is plotted at 104, and that of 1–26103 cells is
plotted at 103. The greater cardiomyogenic ability existed in CD342LSKs than LSKs, and in LSKs than Lin2/lowSca-1+ cells.
doi:10.1371/journal.pone.0062506.g002
Origin of the Bone Marrow-Derived Cardiomyocyte
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e62506
heart and the negative reaction to mouse heart and human cord
blood. By contrast, ryanodine receptor 2 was not detected in any
cardiac specimens derived from human HSC-engrafted recipients.
Although connexin 43 was expressed in all of the recipients, the
expression of connexin 43 was not specific to human cardiomy-
ocytes since it was expressed in human cord blood consistent with
previous reports showing connexin expression on several hema-
topoietic cells [28] (see Table S3). Although the frequency of cell
fusion between donor hematopoietic cells and host cardiomyocytes
is extremely low, we detected the cardiomyocyte-specific expres-
sion of the human cardiomyocyte structural gene, cardiac troponin
C, but not that of other human cardiomyocyte structural genes
such as ryanodine receptor 2 or human cardiac transcription
factors in the cardiac tissue of recipient mice.
Discussion
We have obtained three findings by tracing the fate of
genetically marked BM cells in vivo. First, HSCs generate
cardiomyocytes along with hematopoietic reconstitution. Second,
myeloid lineage cells are primary intermediates for cardiomyocyte
generation. Third, cell fusion with recipient-derived cardiomyo-
cytes is required for the generation of BM-derived cardiomyocytes.
In this study, transplantation of cells derived from GFP-transgenic
mouse into CFP-transgenic recipients enabled us to determine the
mechanism for the generation of donor marker-positive cardio-
myocytes. Moreover, confocal imaging and analyses for the
separation of these two fluorescences led us to address the long-
term question as to the issue of cell fusion or transdifferentiation.
Transplantation of purified HSCs to newborn syngeneic mice
with cardiac injury resulted in the most frequent appearance of
donor-marker+ cardiomyocytes in cardiac tissues. The results
suggest the two possibilities, direct contribution of HSCs to cell
fusion with cardiomyocytes and cell fusion between myeloid
progeny and cardiomyocytes. Previous reports suggest that
purified HSCs do not generate cardiomyocytes when directly
transplanted into myocardium [10,20,21], but can generate
cardiomyocytes following BM transplantation at a low frequency
[4,10,12]. We have shown that cell fusion between BM-derived
myeloid cells and host-derived cardiomyocytes results in the
generation of donor-marker+ cardiomyocytes. The frequency of
BM-derived cardiomyocytes in our study (,0.04%, see Materials
and Methods S1) and other rodent studies (0.001–0.02%)
[4,10,20] are similar to those of host marker-expressing cardio-
myocytes in human cardiac transplantation (0.04–0.16%) [29,30],
which may be the frequency of fusion between circulating myeloid
cells from BM and cardiomyocytes in mammals in general.
Cells of myeloid lineage have been shown to contribute to
skeletal myocytes [31,32], hepatocytes [33,34], or vascular
endothelium [35] in vivo. We report here contribution of BM-
derived myeloid progenitors to the generation of cardiomyocytes.
Actually, several plasma membrane molecules related with cell
Figure 3. CFP expression in the GFP+ BM-derived cardiomyocyte of a CFP-transgenic recipient mouse. (A) Representative image of
fluorescence detection from cardiac tissue of the CFP-transgenic recipient transplanted with GFP+ BM cells. Detected fluorescence images between
417 and 706 nm wavelength at 10–11 nm interval from a cardiac section stained with anti-TnI (Cy3), anti-Cx43 (Cy5), and DAPI are shown
sequentially. (B) The expressions of DAPI, CFP, GFP, Cy3, and Cy5 in the cardiomyocyte shown in (A). Composition of GFP and CFP was examined
simultaneously from each detected image between 449 and 663 nm wavelength (linear unmixing analysis). Detection wavebands used to visualize
each fluorescence are described in each fluorescence image. The cardiomyocyte shown in (A) expressed donor-derived GFP, recipient-derived CFP,
cardiac TnI, and Cx43. (C) Three dimensional analysis of the cardiomyocyte shown in (A) and (B) at the position of each nucleus. In every cross-section
of three planes including nuclei, this cardiomyocyte expressed both GFP and CFP. Merged images (B and C) were obtained from the same confocal
plane. Scale bars = 20 mm.
doi:10.1371/journal.pone.0062506.g003
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fusion were up-regulated in myeloid lineage cells than lymphoid
lineage cells confirmed by qRT-PCR (see Figure S3). Expression
levels of integrin beta 1 [Itgb1] or signal-regulatory protein alpha
[Sirpa] in CMP were 1.73 or 1.82 fold higher than those in CLP,
respectively (n = 3). Of the cells derived from GMPs, monocytic
cells are likely candidates as fusion partners since they have a
physiological capacity for cell fusion [36]. Based on the finding
that CD11blow cells, rather than CD11bhigh cells, within Gr-12/
lowc-Kit2 BM fraction generated cardiomyocytes (unpublished
observations), CD11blow immature monocytes may be the
population contributing to the appearance of donor-marker+
cardiomyocytes similar to the previous report describing the
regeneration of skeletal muscle [32].
The number of donor-derived cells in recipient BM was very
low following the transplantation of Lin2/lowCD452 cells in our
study (Table 1), consistent with previous studies [37,38]. Mesen-
chymal stem cells in the BM are considered to be relatively
resistant to irradiation compared with HSCs [37,38]. Therefore,
the lack of donor-derived cardiomyocytes following systemic
infusion of Lin2/lowCD452 cells into sublethally irradiated mice
may be due to inefficient engraftment of injected MSCs in the
recipient BM. Intra-BM injection of 105 GFP-labeled clonally
purified MSCs (CMG cells) resulted in the generation of donor-
marker+ cardiomyocytes [11]. Our results, together with the report
showing little ability of MSCs to give rise to cardiomyocytes
following intravenous or intramyocardial transplantation [8],
imply that administration route and cell preparation need to be
extensively assessed for cell therapy using MSCs. We examined
whether BM-derived mesenchymal cells gain a cardiomyocyte
phenotype through differentiation or cell fusion with a coculture
experiment using GFP-expressing BM mesenchymal cells and
adult cardiomyocytes. In the experiment, one GFP+ cell expressing
cardiomyocyte-specific antigens was detected (unpublished obser-
vations). However, the function of the cardiac-maker positive cell
as a cardiomyocyte is unknown. A previous study demonstrated
that mesenchymal stromal cell-derived cells acquiring cardiomy-
ocyte phenotypic characteristics do not exhibit sufficient electrical
property [39]. Additionally, improvement of cardiac function via
mesenchymal stem/stromal cell transplantation is thought to be
mediated by paracrine mechanism in addition to the direct
contribution of cardiac marker-positive mesenchymal stem/
stromal cells in themselves as contractile cardiomyocytes [40,41].
Recent report suggests that mesenchymal stromal cells recruit
monocytes/macrophages secreting IL-10 or TGF-b [41]. Macro-
phages contributing to anti-inflammatory status could be one of
the determinants for tissue regeneration in a mouse model for
myocardial infarction [41]. Therefore, whether HSCs and MSCs
act synergistically to regenerate cardiac tissue or to inhibit
apoptosis in damaged cardiac tissue should be evaluated by using
a large animal model in the future.
To establish regenerative medicine for heart failure patients,
long-term improvement in cardiac function is important. Self-
renewing cardiac-resident stem/progenitor cells [42,43] could
maintain a pool for cardiomyocyte turnover [44,45]. BM could be
one of the reservoirs that can give rise to cardiac-resident stem cells
[46] and cells of multiple lineages [47]. Indeed, cardiomyocyte
renewal in adult mammals is demonstrated under the physiological
condition [48] or after injury [1]. Therefore, it should be
demonstrated in the future to what degree BM-derived stem/
progenitor cells and cardiac stem/progenitor cells contribute to
turnover and regeneration of cardiomyocytes in the physiological
or pathological conditions and whether BM-derived stem/
progenitor cells can generate cardiac stem/progenitor cells.
Finally, we have demonstrated the contribution of myeloid
lineage cells to cardiomyocytes through cell fusion. Recent reports
suggest that stem cell fusion with the cardiomyocyte could add
contractile function to the injured heart [49], and BM cell
transplantation can restore impaired cardiac function [7].
Identification of the specific cell type and factors involved in cell
fusion may lead to the enhancement of therapeutic effects of
ongoing clinical cell therapy. In our qPCR analysis, two out of 6
donor cardiomyocyte-specific genes were detected in recipient
cardiac tissues. Considering the low frequency of cell fusion, future
in vitro and in vivo experiments might be required to determine as
to how far reprogramming process occurs following cell fusion.
Altogether, our findings suggest that myeloid progenitors may
potentially serve as a readily available source of effecter cells for
targeted cellular therapy of cardiac disorders through cell fusion.
Materials and Methods
Mice
C57BL/6 mice transgenically expressing enhanced GFP driven
by the cytomegalovirus (CMV) enhancer/chicken b-actin pro-
moter were kindly provided by Dr. M. Okabe (Osaka University).
C57BL/6 mice transgenically expressing enhanced CFP driven by
the CMV enhancer/chicken b-actin promoter, NOD/SCID/
IL2rcnull mice, and NOD.Rag1nullIL2rcnull mice were obtained
from the Jackson Laboratory (Bar Harbor, ME). C57BL/
6.Rag2nullIL2rcnullNOD-Sirpa mice were generated in our labo-
ratory. All mice were bred and maintained under defined flora.
Experiments were performed according to the guidelines approved
by the Institutional Animal Committee of Kyushu University
(Approval ID: 18–68). PB sampling from recipient mice was
performed under deep inhalation anesthesia. BM and heart were
dissected out from donor/recipient mice sacrificed by cervical
dislocation under deep inhalation anesthesia.
Purification of Donor Cells
BM cells were harvested from GFP-transgenic mice at 8–12
weeks of age by flushing femurs and tibiae. MNCs were isolated by
gradient centrifugation. Rat anti-mouse lineage antigen (BD
Pharmingen, Caltag) and sheep anti-rat IgG antibody-conjugated
immunomagnetic beads (Dynal) were used to deplete mature
hematopoietic cells from MNCs. For separation of Lin2/lowCD45+
cells and Lin2/lowCD452 cells and enrichment of Lin2/lowSca-1+
cells or Lin2/lowc-Kit+ cells by magnetic cell sorting, immuno-
magnetic microbeads (Miltenyi Biotec) were used. For purification
of each BM stem/progenitor fraction by FACS, enriched BM cells
were labeled by fluorescence-conjugated antibodies (see Materials
and Methods S1). Umbilical cord blood cells were collected during
normal full-term delivers after obtained written informed consent
(provided by Kyushu Block Red Cross Blood Center, Japan Red
Cross Society). Experiments using cord blood were performed
according to the guidelines approved by the Institutional
Committee of Kyushu University (Approval ID: 17–114). MNCs
were separated by Ficoll-Hypaque density-gradient centrifugation.
Lineage-depleted cord blood cells were obtained magnetically
(Miltenyi Biotec). Sorting of CD34+CD382 subfractions was
accomplished by staining lineage-depleted cord blood cells with
fluorescein isothiocyanate (FITC)-conjugated anti-CD34, and
phycoerythrin (PE)-conjugated anti-CD38 (BD Biosciences). Cell
sorting was performed on a FACSAria (BD).
Transplantation
Unfractionated or purified BM cells from GFP mice were
injected intravenously into C57BL/6 mice or CFP-transgenic mice
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within 48 hours of birth after 560 cGy irradiation. Left ventricular
wall injury was induced by puncturing newborn recipient heart
with a 29 G needle following transplantation of donor BM cells.
Five to ten thousand Lin2CD34+CD382 cells from human cord
blood were transplanted into immune-compromised mice after
irradiation.
Flow Cytometric Analysis of Recipient PB and BM
PB was collected from retro-orbital plexus of recipients, and BM
cells were harvested from femurs and tibiae. The percentage of
GFP+ cells in PB and BM of recipients was examined by flow
cytometric analysis using FACSCalibur (BD). PB and BM of
recipients were labeled with each biotin-conjugated anti-mouse
lineage antigen (CD3e, CD11b, B220, Gr-1, and TER-119)
antibody, subsequently labeled with Cy3-conjugated streptavidin
(Jackson ImmunoResearch) to recognize myeloid cells (CD11b,
Gr-1), T lymphocytes (CD3e), and B lymphocytes (B220) by flow
cytometric analysis. FACS lysing solution (BD) was used to lyse red
blood cells following antibody labeling.
Histological Analysis
Recipient hearts were removed and perfused with PBS to
eliminate blood cells immediately after they were sacrificed by
cervical dislocation. For immunofluorescence staining, recipient
hearts were sectioned into 100-mm slices from apex to base with a
vibratome (DTK-1000, D.S.K.) following fixation in 4% parafor-
maldehyde and dehydration in 70% ethanol. Vibratome-sectioned
cardiac slices were stained with primary antibodies to CD45
(DakoCytomation), CD11b (BD Pharmingen), vimentin (Sigma),
cardiac troponin I (TnI; Santa Cruz Biotechnology), and
connexin43 (Cx43; Chemicon). Secondary antibodies conjugated
with Cy3 or Cy5 (Jackson ImmunoResearch) were used to
visualize primary antibodies. Forty contiguous cardiac sections
per a recipient mouse were carefully examined for the presence of
GFP+ cardiomyocytes by laser-scanning confocal microscopy
(LSM-GB200, Olympus). In the transplantation of GFP+ BM
cells into CFP-transgenic mice, linear unmixing analysis was
employed to distinguish GFP+ donor-derived cells, GFP+CFP+
fused cells, and CFP+ recipient-derived cells as described
previously [12] (LSM510 META, Carl Zeiss, see Materials and
Methods S1).
Quantitative Real-time Polymerase Chain Reaction
Total RNA was extracted from recipient heart, non-recipient
mouse heart, human cord blood, and 104 cells each of sorted
mouse hematopoietic cells. Reverse transcription was performed
using SuperScript II or SuperScript III (Invitrogen) according to
the manufacturer’s instructions. For human-specific cardiac
transcription factors and cardiomyocyte structural genes, qRT-
PCR was performed on the synthesized complementary deoxyri-
bonucleic acid (cDNA) with Platinum Quantitative PCR Super-
Mix (Invitrogen) on LightCycler 480 (Roche) to determine cycle
thresholds (CT) of amplification. Human heart QUICK-Clone
cDNA (Clontech) was used as a positive control. Human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
as the internal control. For mouse adhesion molecules, qRT-PCR
was performed on Applied Biosystems 7500 real-time PCR system
with TaqMan(R) primer-probe sets provided from Applied
Biosystems. 18 s rRNA was used as the internal control. Sequences
of dual-labeled fluorogenic probes and gene-specific primers
(Sigma-Aldrich), and product ID of TaqMan(R) Gene Expression
Assay (Applied Biosystems) are listed on Table S4. For initial
normalization to the housekeeping gene, the difference in CT
value (DCT= [CT gene of interest] – [CT human GAPDH or 18 s
rRNA]) was determined on each sample. Relative expression levels
of each mRNA were calculated as the ratio to levels of human
heart or mouse CLP cDNA using the comparative CT (2
2DDCt)
method [50].
Statistical Analysis
Results are presented as mean +/2 standard deviation (S.D.).
Probability values were calculated by using the Mann-Whitney U
test (non-parametric independent two-group comparison) or the
Pearson’s correlation coefficient test. A probability value of less
than 0.05 was considered to be statistically significant.
Supporting Information
Figure S1 Differentiation capacities of Lin2/lowCD452 cells. (A)
CD45 expression of Lin2/lowMNCs, separated Lin2/lowCD45+
cells, and separated Lin2/lowCD452 cells. (B) Bright-field and
fluorescence image of GFP+Lin2/lowCD452 cells following
culture. Polygonal or spindle-shaped adherent GFP+ cells were
recognized as mesenchymal cells. (C) In vitro differentiation of
Lin2/lowCD452 cells into osteoblasts (left) or adipocytes (right) by
induction using differentiation media for each. Differentiation into
osteoblasts or adipocytes was confirmed by alkaline phosphatase
staining (left; red) or Oil red O staining (right; lipid vacuoles are
stained in red), respectively. (D) Bone section of recipients
transplanted with GFP+Lin2/lowCD452 cells stained with anti-
GFP (red, Cy3), anti-CD45 (yellow, Cy5), and DAPI (blue). Bright-
field image is shown at leftmost. GFP+CD452 cells were present
within bone cortex (white arrows). These results suggest that
separated Lin2/lowCD452 cells contain MSCs that can differen-
tiate into multiple mesenchymal lineages. Merged images were
obtained from the same confocal plane. Scale bars = 20 mm.
(TIF)
Figure S2 Flow cytometric analysis of recipient hematopoietic
tissues. Representative image of flow cytometric analysis of
recipient PB and BM transplanted with FACS-purified LSKs,
and recipient PB transplanted with total myeloid progenitors (My-
P) or CLPs. In LSK recipients, donor-derived GFP+ myeloid cell
lineage (Gr-1+ or CD11b+), B cell lineage (B220+), and T cell
lineage (CD3e+) were confirmed. Donor-derived myeloid cell
lineage (Gr-1+ or CD11b+) was predominantly present in
recipients transplanted with total myeloid progenitors, and
donor-derived B/T cell lineage (B220+ or CD3e+) was predom-
inantly present in recipients transplanted with CLPs.
(TIF)
Figure S3 Relative cDNA expression of adhesion molecules in
myeloid and lymphoid lineages. The averages of relative cDNA
expressions from three qRT-PCR experiments are indicated by
histogram with positive standard deviation. Expression levels of
Itgb1 and Sirpa in CMP were higher than those in CLP.
Expression levels of Itgb1, Sirpa, and Adam9 in myeloid
derivatives (neutrophil, monocyte) were higher than those in
lymphoid derivatives (T lymphocyte, B lymphocyte). In the four
adhesion molecules examined (Itgb1, Sirpa, Adam9, and Ad-
am12), Adam12 was not detected in any of the samples. Gene
names corresponding to each gene symbol, probes and primers
information are described in Table S4.
(TIF)
Table S1 The number of donor-derived cardiomyocytes after
serial transplantation.
(XLS)
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Table S2 CFP expression of donor-derived GFP+ cardiomyo-
cytes in CFP recipient mice.
(XLS)
Table S3 Relative cDNA expression to human heart.
(XLS)
Table S4 Probes and primers for quantitative real-time
polymerase chain reaction (qRT-PCR).
(XLS)
Materials and Methods S1 Detailed information on purifica-
tion of donor BM cells, cell culture and differentiation assay of
Lin2/lowCD452 cells, and histological analysis.
(DOC)
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